Novartis said pelacarsen lowered Lp(a) in patients already on guideline-directed care, but Lp(a)HORIZON missed its cardiovascular composite versus placebo. The first large outcomes test of the inherited risk factor now hangs over later trials from Amgen and Lilly.
Newsletter
Pipeline, markets, policy, and science. Once a week.
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.
MariTide delivered up to about 20% mean weight loss at 52 weeks without a plateau, then Amgen lost about $7 billion in market value. The remaining fight is GIP direction, first-dose gut burden, and conjugate manufacturing cost.
Suzetrigine beat placebo on SPID48 in both pivotal acute-pain trials, then failed the superiority test against hydrocodone/acetaminophen, including a statistically significant loss in bunionectomy.